T1	Participants 102 162	non-small cell lung cancer not suitable for curative therapy
T2	Participants 743 895	Patients were eligible if they had stage I-IIIB NSCLC, unsuitable for curative therapy, or stage IV with a PET-detected extracranial solitary metastasis
#1	AnnotatorNotes T2	non-small cell lung cancer (NSCLC)
T3	Participants 1290 1327	Eighty-four patients were randomized.
